CITF Research Results

CITF Research Results2022-01-27T09:23:33-05:00

Vaccination in individuals living with immune-mediated inflammatory diseases is highly effective against SARS-CoV-2 infection and severe outcomes

New findings from the CITF-funded SUCCEED project, published in The Lancet Rheumatology, indicate that two doses of mRNA vaccines were 79 to 89% effective at preventing SARS-CoV-2 infection in individuals living with immune-mediated inflammatory diseases in Ontario.

May 2, 2022|Higher risk due to health condition|

Vaccine intentions and perceptions among public school staff within the Greater Vancouver Area

In a paper published in Frontiers in Public Health, CITF-funded researchers Drs. Pascal Lavoie, Louise Mâsse and Allison Watts, along with colleagues from the University of British Columbia, explored the factors associated with the intention to get the COVID-19 vaccine, as well as the sense of urgency to get vaccinated, among school staff.

April 28, 2022|General vaccine surveillance|

Effectiveness of COVID-19 vaccines against hospitalization and death across Canada

CITF-funded researchers Drs. Jeff Kwong from the University of Toronto, Gaston de Serres from l'Institut national de santé publique du Québec, and Mel Krajden of the University of British Columbia, found that two doses of mRNA or viral vector (Astra Zeneca) vaccines provide excellent protection against severe outcomes (hospitalization or death) from COVID-19.

April 22, 2022|General vaccine surveillance|
Go to Top